Table 2.
Patient and disease characteristics and previous randomized arm by treatment group
| No pulses, N = 205, n (%) | Pulses, N = 206, n (%) | |
|---|---|---|
| EORTC risk group given at randomization | ||
| AR1 | 159 (77.6) | 160 (77.7) |
| AR2 | 46 (22.4) | 46 (22.3) |
| Sex | ||
| Female | 98 (47.8) | 100 (48.5) |
| Male | 107 (52.2) | 106 (51.5) |
| First randomization | ||
| PRED | 101 (49.3) | 101 (49.0) |
| DEX | 100 (48.8) | 101 (49.0) |
| Not randomized | 4 (2.0) | 4 (1.9) |
| Second randomization | ||
| Short asparaginase | 99 (48.3%) | 99 (48.1) |
| Long asparaginase | 94 (45.9%) | 94 (45.6) |
| Not randomized | 12 (5.9) | 13 (6.3) |
| Age, y | ||
| Younger than 1 | 0 (0.0) | 2 (1.0) |
| 1 to younger than 2 | 15 (7.3) | 14 (6.8) |
| 2 to younger than 6 | 98 (47.8) | 81 (39.3) |
| 6 to younger than 10 | 42 (20.5) | 51 (24.8) |
| 10 or older | 50 (24.4) | 58 (28.2) |
| WBC count, ×109/L | ||
| Fewer than 25 | 141 (68.8) | 164 (79.6) |
| 25 to fewer than 100 | 51 (24.9) | 28 (13.6) |
| 100 or more than 100 | 13 (6.8) | 14 (6.8) |
| NCI risk group | ||
| Standard risk | 134 (65.4) | 128 (62.1) |
| High risk | 71 (34.6) | 78 (37.9) |
| Disease | ||
| ALL | 195 (95.1) | 189 (91.7) |
| NHL | 10 (4.9) | 17 (8.3) |
| Immunophenotype | ||
| B-lineage | 175 (85.4) | 172 (83.5) |
| T-lineage | 30 (14.6) | 34 (16.5) |
| CSF status12 | ||
| CNS-1 | 180 (87.8) | 184 (89.3) |
| CNS-2 + TLP | 22 (10.7) | 21 (10.2) |
| CNS-3 | 3 (1.5) | 1 (0.5) |
AR indicates average risk; PRED, prednisolone; DEX, dexamethasone; WBC, white blood cell; NCI, National Cancer Institute; CSF, cerebrospinal fluid; CNS, central nervous system; and TLP, traumatic lumbar puncture.